Sign In
Buy SANA
$3.12
-0.120 (-3.70%)
At Close: Jun 03, 2026
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
06:11pm, Tuesday, 02'nd Jun 2026
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible
Sana Biotechnology to Present at June 2026 Investor Conferences
04:05pm, Wednesday, 27'th May 2026
SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
09:00am, Friday, 15'th May 2026
SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold a
Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:30am, Wednesday, 13'th May 2026
Sana Biotechnology, Inc. (SANA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
04:05pm, Monday, 11'th May 2026
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451
Sana Biotechnology to Present at the BofA Securities 2026 Healthcare Conference
04:05pm, Tuesday, 05'th May 2026
SEATTLE, May 05, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract
Brokerages Set Sana Biotechnology, Inc. (NASDAQ:SANA) Target Price at $8.00
01:31am, Friday, 27'th Mar 2026
Sana Biotechnology, Inc. (NASDAQ: SANA - Get Free Report) has earned a consensus rating of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat.com reports. O
Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript
04:52am, Wednesday, 18'th Mar 2026
Sana Biotechnology, Inc. (SANA) Presents at The Citizens Life Sciences Conference 2026 Transcript
Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
01:46pm, Friday, 06'th Mar 2026
Sana Biotechnology, Inc. (SANA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
04:05pm, Tuesday, 03'rd Mar 2026
Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evad
Sana Biotechnology to Present at March 2026 Investor Conferences
04:05pm, Monday, 23'rd Feb 2026
SEATTLE, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webca
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
11:51am, Friday, 20'th Feb 2026
Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
Sana Biotechnology: A Small, Speculative Play
03:24am, Friday, 13'th Feb 2026
Sana Biotechnology pivots to focus on its SC451 hypoimmune cell therapy for type 1 diabetes, aiming for a functional cure. Recent single-patient data validate SANA's immune-evasion technology, driving
